HER2-positive breast cancer has a poor prognosis, but it is not the worst type of breast cancer. The survival time of HER2-positive breast cancer patients needs to be combined with the specific pathological staging. For breast cancer diagnosed at early stage, the 5-year survival rate of timely surgical treatment can reach more than 80%, and even some patients can survive for more than 20 years. Especially for HER2-positive and estrogen-progestogen receptor-positive patients, the choice of adjuvant treatment plan after surgery also needs to be based on detailed pathological staging and lymph node metastasis. In addition, if Her2-positive breast cancer reaches an advanced stage with lymph node metastasis or even distant metastasis, the prognosis is very poor and generally incurable. It is necessary to go to the hospital regularly for review and further chemotherapy, radiotherapy and targeted therapy according to medical advice. At present, there are PARP inhibitors and immunotherapy, but also need to go to the hospital for regular checkups.